The yeast infection diagnostics market size is projected to be worth US$ 417.7 Million in 2023. The market is likely to surpass US$ 711.4 Million by 2033 at a CAGR of 5.5% during the forecast period. Growing yeast infection incidences is aiding the market growth. When the vagina is infected with Candida, it is referred to as a yeast infection. Candida is a kind of yeast. Candidiasis is most typically seen as a secondary illness in immunocompromised people. These are frequent dwellers in the mouth cavity, gastrointestinal tract, vagina, penis, and other areas. They only become pathogenic when favorable conditions exist. It can affect the mouth, vagina, penis, and other areas of the body. Antibiotic use is frequently linked to candidiasis. Cancer cytotoxic treatment can produce Candida albicans fungemia, which develops from fungal translocation across damaged mucosal barriers. Candidiasis is more common in old age and infants, according to NIH: StatPearls 2023. Yeast infection affects around 37% of newly born newborns in the United States.
Other Drivers Propelling the Demand for Yeast Infection Diagnostics Market include:
Challenges for Companies /Manufacturers in the Yeast Infection Diagnostics Market:
Opportunities in the Yeast Infection Diagnostics Market Industry:
Latest Trends in the Yeast Infection Diagnostics Market:
| Attributes | Details |
|---|---|
| Yeast Infection Diagnostics Market Size (2023) | US$ 417.7 Million |
| Yeast Infection Diagnostics Market Projected Size (2033) | US$ 711.4 Million |
| Value CAGR (2023 to 2033) | 5.5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
From 2012 to 2022, the global yeast infection diagnostics market experienced a CAGR of 4.4%, reaching a market size of US$ 417.7 Million in 2023.
From 2012 to 2022, the global yeast infection diagnostics market industry witnessed steady growth due to the increased prevalence of yeast infection. According to COVID-19, fungal infections can cause serious disease and death. COVID-19 with a fungal infection can coexist in some people. COVID-19 therapies, such as steroids and other medicines, can reduce the body's ability to fight fungus.
The creation of diagnostic kits has been facilitated by advances in genomic research and understanding of the genetic underpinnings of yeast specific biomarker.
Future Forecast for Yeast Infection Diagnostics Market Industry:
Looking ahead, the global Yeast Infection Diagnostics Market industry is expected to rise at a CAGR of 5.5% from 2023 to 2033. During the forecast period, the market size is expected to reach US$ 711.4 Million by 2033.
The yeast infection diagnostics market industry is expected to continue its growth trajectory from 2023 to 2033. Next generation sequencing has made diagnosis of causal species easy, with intervention of other detection techniques and artificial intelligence. Diagnosis process is prone to become easy, rapid and in small point-of-care testing.
Early identification and diagnosis of yeast infection improves patient health outcomes significantly. Yeast infection diagnostics offer the ability to detect infection and type of causal agent in early-stage of infection, allowing for earlier intervention and better survival rates. The emphasis on early diagnosis is anticipated to drive future demand for yeast infection diagnostic market.
| Country | The United States |
|---|---|
| Market Size (US$ Million) by End of Forecast Period (2033) | US$ 204.9 Million |
| CAGR % 2023 to End of Forecast (2033) | 4.5% |
The Yeast Infection Diagnostics Market industry in the United States is expected to reach a market size of US$ 204.9 Million by 2033, expanding at a CAGR of 4.5%. Vaginal candidiasis is the most prevalent among all the yeast infections, according to the Centers for Disease Control and Prevention 2022. It is considered to be the second most prevalent kind of vaginal infection in the USA, following bacterial vaginal infections. Annually, around 1.4 million outpatient consultations for vaginal candidiasis are made.
| Country | The United Kingdom |
|---|---|
| Market Size (US$ Million) by End of Forecast Period (2033) | US$ 51.6 million |
| CAGR % 2023 to End of Forecast (2033) | 3.7% |
The yeast infection diagnostics market industry in the United Kingdom is expected to reach a market value of US$ 51.6 Million, expanding at a CAGR of 3.7% during the forecast period. According to the 2013 Health Technology Assessment, Candida albicans represented 61% of all Invasive fungal disease. According to an article provided by Public Health England 2021, the overall incidence of Candidaemia in England was 3.5 every 100,000 inhabitants in 2020, a modest rise from 2019 (3.1 per 100,000), with older people having the most severe prevalence of Candidaemia.
The rise in frequency between 2019 to 2020 might be attributed to a significant rise in the number of patients referred to intensive care units (ICUs) in the year 2020 as an outcome of the COVID-19 pandemic. Patients in ICUs are more likely to develop Candidaemia because the environment permits the opportunistic pathogen to grow invasive, and multiple risk factors underlying Candidaemia overlap with features of ICU patients. The present epidemiologic demographics of IFD in UK critical care units is described in the aforementioned paragraph.
| Country | China |
|---|---|
| Market Size (US$ Million) by End of Forecast Period (2033) | US$ 64.8 million |
| CAGR % 2023 to End of Forecast (2033) | 6.8% |
The yeast infection diagnostics market industry in China is anticipated to reach a market size of US$ 64.8 million, moving at a CAGR of 6.8% during the forecast period. The yeast infection diagnostics market industry in China is expected to grow prominently due to the increasing commercial intervention in production of rapid diagnostic kits and real time PCR kits. As per The Lancet Infectious Diseases today 2018, Chinese, women are the world’s most numerous sufferers of thrush at 29.1 million.
| Country | Japan |
|---|---|
| Market Size (US$ Million) by End of Forecast Period (2033) | US$ 48.2 million |
| CAGR % 2023 to End of Forecast (2033) | 6.4% |
The yeast infection diagnostics market industry in Japan is estimated to reach a market size of US$ 48.2 million by 2033, thriving at a CAGR of 6.4%. When pre-reproductive and reproductive population are nearly comparable in quantity or proportion, and post-reproductive population have very few, bell-shaped age pyramids arise. Japanese demography reflects a curve with a bell shape, indicating that Japan has a larger elderly population. According to Geriatrics (Basel) 2020, there is an elevated prevalence of oral Candidiasis diagnosis in reliant Japanese elderly people. When contrasted with independent older adults, dependent seniors might be more prone to oral Candida albicans infection. As a result, Japan has emerged as a key market for yeast infection diagnostics.
| Country | South Korea |
|---|---|
| Market Size (US$ Million) by End of Forecast Period (2033) | US$ 5.1 Million |
| CAGR % 2023 to End of Forecast (2033) | 8.2% |
The yeast infection diagnostics market industry in South Korea is expected to reach a market size of US$ 5.1 million, expanding at a CAGR of 8.2% during the forecast period. South Korea is well-known for its technology breakthroughs and healthcare innovation. The country's strong emphasis on research and development, along with a favorable regulatory framework, leads to the growth of the yeast infection diagnostics market by allowing the development and commercialization of improved diagnostic technologies.
Principal Consultant
The test strips are predominant in yeast infection diagnostics market industry with a market share of 60.2% in 2022. Antifungal susceptibility testing (AFST) is currently frequently utilized and recommended in the treatment of patients suffering from persistent fungal infections like candidiasis and aspergillosis. The average vaginal pH ranges from 3.8 to 5.0. During a vaginal infection, the pH rises to 5.0-5.5 or 6.0-7.5, and vulvovaginal candidiasis is responsible for 20% to 25% of all vaginitis cases. The test strip is used to detect changes in vaginal pH; it is a tiny, paper-like strip that is put into the vagina for a few seconds before being compared to a color chart to ascertain the pH level.
The vaginal pH Test constitutes 61.9% market share globally in 2022. Vaginal pH strip is more prominently used as it is easy to use by the patients. The strip is cost effective with comparison to the other diagnostic kits. It is more convenient and non-invasive method for initial screening of yeast infection.
The Hospitals are dominating the yeast infection diagnostics market with the market share of 39.2% in 2022. A hospital is able to cut expenses by offering a complete range of services to patients. Doctors can utilize a variety of diagnostic tests to determine the source of a patient's symptoms. A commitment to provide high-quality care at a reasonable cost. A hospital can assist in identifying potential issues early on, before they become more serious. It enables rapid intervention and therapy, which improves the results for patients.
The market for yeast infection diagnostics is very competitive, with numerous businesses vying for market supremacy. In order to remain a step ahead of the competition in a scenario like this, major players have to implement smart strategies.
Key Strategies Used by the Participants
Key players focus on developing and introducing innovative products to address unmet needs in the market. They invest in research and development to improve existing formulations, delivery systems, and enhance the efficacy and safety of the products
Key players often form strategic partnerships and collaborations with other companies, research institutes, or healthcare organizations, these partnerships allow for knowledge sharing, joint research and development efforts, and access to complementary technologies or expertise.
Key players strive to expand their presence in different geographic regions to tap into new markets and reach a wider customer base. They may establish subsidiaries, distribution networks. Or strategic alliances in various countries to strengthen their market position.
Companies in the market may engage in mergers or acquisitions to consolidate their product portfolio, acquire new technologies, these strategic moves allow companies to enter new market segments, gain access to novel products or intellectual property, and achieve synergies in terms of research, manufacturing, or distributions.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Key Developments in the Yeast Infection Diagnostics Market:
An increase in technological advancements drives the demand.
The rapid and reliable detection of a small number of infectious agents drives sales.
The market expands at a CAGR of 5.5% from 2023 to 2033.
The increase in commercial intervention in the production of rapid diagnostic kits raises the demand in China.
China is likely to expand at a CAGR of 6.8% from 2023 to 2033.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Value Added Insights
4.1. Product Adoption / Usage Analysis
4.2. Recent Product Approvals/Launches
4.3. Regulatory Landscape
4.4. Statistics of Yeast infection & Treatment Procedures
4.5. PESTEL Analysis
4.6. Porter’s Analysis
4.7. Unmet Needs for Diagnostic Kits
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Healthcare Expenditure Outlook
5.1.2. Global Medical Device Outlook
5.1.3. Global Life Expectancy Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Key Player’s Historic Growth
5.2.2. Growing Awareness about Cancer Diseases
5.2.3. Favourable Government Regulations
5.2.4. Rising Demand for Minimally Invasive Procedures
5.2.5. Technological Advancement in the Devices
5.2.6. Increasing Prevalence of Yeast Infection
5.3. Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Volume (in Units) Analysis 2012 to 2022 and Forecast, 2023 to 2033
6.1. Historical Volume (in Units) Analysis, 2012 to 2022
6.2. Current and Future Volume (in Units) Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
7. Global Market - Pricing Analysis
7.1. Regional Pricing Analysis By Product
7.2. Pricing Break-up
7.2.1. Manufacturer Level Pricing
7.2.2. Distributor Level Pricing
7.3. Global Average Pricing Analysis Benchmark
7.4. Pricing Assumptions
8. Global Market Demand (in Value or Size in US$ Mn) Analysis 2012 to 2022 and Forecast, 2023 to 2033
8.1. Historical Market Value (US$ Million) Analysis, 2012 to 2022
8.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
8.2.1. Y-o-Y Growth Trend Analysis
8.2.2. Absolute $ Opportunity Analysis
9. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Product
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Product, 2012 to 2022
9.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Product, 2023 to 2033
9.3.1. Strips
9.3.2. Cassettes
9.3.3. Panel Test
9.4. Market Attractiveness Analysis By Product
10. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Test Type
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis By Test Type, 2012 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Test Type, 2023 to 2033
10.3.1. Vaginal pH Test
10.3.2. Nucleic Acid Amplification Testing (NAAT)
10.3.3. Microbiome Test
10.4. Market Attractiveness Analysis By Test Type
11. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Body Part
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis By Body Part, 2012 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Body Part, 2023 to 2033
11.3.1. Vagina
11.3.2. Penis
11.3.3. Mouth
11.3.4. Nail
11.3.5. Skin folds
11.4. Market Attractiveness Analysis By Body Part
12. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Indication
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Analysis By Indication, 2012 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
12.3.1. Vulvovaginal Candidiasis
12.3.2. Trichomoniasis
12.3.3. Chlamydia
12.3.4. Gonorrhea
12.3.5. Bacterial Vaginosis
12.4. Market Attractiveness Analysis By Indication
13. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By End User
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Million) Analysis By End User, 2012 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033
13.3.1. Hospitals
13.3.2. Diagnostic Laboratories
13.3.3. Specialty Clinics
13.3.4. Homecare Settings
13.4. Market Attractiveness Analysis By End User
14. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, by Region
14.1. Introduction
14.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Region, 2012 to 2022
14.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Region, 2023 to 2033
14.3.1. North America
14.3.2. Latin America
14.3.3. Europe
14.3.4. South Asia
14.3.5. East Asia
14.3.6. Oceania
14.3.7. Middle East and Africa (MEA)
14.4. Market Attractiveness Analysis By Region
15. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2012 to 2022
15.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. USA
15.3.1.2. Canada
15.3.2. By Product
15.3.3. By Test Type
15.3.4. By Body Part
15.3.5. By Indication
15.3.6. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product
15.4.3. By Test Type
15.4.4. By Body Part
15.4.5. By Indication
15.4.6. By End User
15.5. Country Level Analysis & Forecast
15.5.1. USA Market Analysis
15.5.1.1. .Introduction
15.5.1.2. Market Analysis and Forecast by Market Taxonomy
15.5.1.2.1. By Product
15.5.1.2.2. By Test Type
15.5.1.2.3. By Body Part
15.5.1.2.4. By Indication
15.5.1.2.5. By End User
15.5.2. Canada Market Analysis
15.5.2.1. Introduction
15.5.2.2. Market Analysis and Forecast by Market Taxonomy
15.5.2.2.1. By Product
15.5.2.2.2. By Test Type
15.5.2.2.3. By Body Part
15.5.2.2.4. By Indication
15.5.2.2.5. By End User
15.6. Market Trends
15.7. Key Market Participants - Intensity Mapping
15.8. Drivers and Restraints - Impact Analysis
16. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2012 to 2022
16.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. Brazil
16.3.1.2. Mexico
16.3.1.3. Argentina
16.3.1.4. Rest of Latin America
16.3.2. By Product
16.3.3. By Test Type
16.3.4. By Body Part
16.3.5. By Indication
16.3.6. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product
16.4.3. By Test Type
16.4.4. By Body Part
16.4.5. By Indication
16.4.6. By End User
16.5. Country Level Analysis & Forecast
16.5.1. Brazil Market Analysis
16.5.1.1. .Introduction
16.5.1.2. Market Analysis and Forecast by Market Taxonomy
16.5.1.2.1. By Product
16.5.1.2.2. By Test Type
16.5.1.2.3. By Body Part
16.5.1.2.4. By Indication
16.5.1.2.5. By End User
16.5.2. Mexico Market Analysis
16.5.2.1. Introduction
16.5.2.2. Market Analysis and Forecast by Market Taxonomy
16.5.2.2.1. By Product
16.5.2.2.2. By Test Type
16.5.2.2.3. By Body Part
16.5.2.2.4. By Indication
16.5.2.2.5. By End User
16.5.3. Argentina Market Analysis
16.5.3.1. Introduction
16.5.3.2. Market Analysis and Forecast by Market Taxonomy
16.5.3.2.1. By Product
16.5.3.2.2. By Test Type
16.5.3.2.3. By Body Part
16.5.3.2.4. By Indication
16.5.3.2.5. By End User
16.6. Market Trends
16.7. Key Market Participants - Intensity Mapping
16.8. Drivers and Restraints - Impact Analysis
17. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2012 to 2022
17.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. Germany
17.3.1.2. France
17.3.1.3. Italy
17.3.1.4. UK
17.3.1.5. Spain
17.3.1.6. Russia
17.3.1.7. BENELUX
17.3.1.8. Rest of Europe
17.3.2. By Product
17.3.3. By Test Type
17.3.4. By Body Part
17.3.5. By Indication
17.3.6. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product
17.4.3. By Test Type
17.4.4. By Body Part
17.4.5. By Indication
17.4.6. By End User
17.5. Country Level Analysis & Forecast
17.5.1. Germany Market Analysis
17.5.1.1. .Introduction
17.5.1.2. Market Analysis and Forecast by Market Taxonomy
17.5.1.2.1. By Product
17.5.1.2.2. By Test Type
17.5.1.2.3. By Body Part
17.5.1.2.4. By Indication
17.5.1.2.5. By End User
17.5.2. France Market Analysis
17.5.2.1. Introduction
17.5.2.2. Market Analysis and Forecast by Market Taxonomy
17.5.2.2.1. By Product
17.5.2.2.2. By Test Type
17.5.2.2.3. By Body Part
17.5.2.2.4. By Indication
17.5.2.2.5. By End User
17.5.3. Italy Market Analysis
17.5.3.1. Introduction
17.5.3.2. Market Analysis and Forecast by Market Taxonomy
17.5.3.2.1. By Product
17.5.3.2.2. By Test Type
17.5.3.2.3. By Body Part
17.5.3.2.4. By Indication
17.5.3.2.5. By End User
17.5.4. UK Market Analysis
17.5.4.1. .Introduction
17.5.4.2. Market Analysis and Forecast by Market Taxonomy
17.5.4.2.1. By Product
17.5.4.2.2. By Test Type
17.5.4.2.3. By Body Part
17.5.4.2.4. By Indication
17.5.4.2.5. By End User
17.5.5. Spain Market Analysis
17.5.5.1. .Introduction
17.5.5.2. Market Analysis and Forecast by Market Taxonomy
17.5.5.2.1. By Product
17.5.5.2.2. By Test Type
17.5.5.2.3. By Body Part
17.5.5.2.4. By Indication
17.5.5.2.5. By End User
17.5.6. Russia Market Analysis
17.5.6.1. .Introduction
17.5.6.2. Market Analysis and Forecast by Market Taxonomy
17.5.6.2.1. By Product
17.5.6.2.2. By Test Type
17.5.6.2.3. By Body Part
17.5.6.2.4. By Indication
17.5.6.2.5. By End User
17.5.7. BENELUX Market Analysis
17.5.7.1. .Introduction
17.5.7.2. Market Analysis and Forecast by Market Taxonomy
17.5.7.2.1. By Product
17.5.7.2.2. By Test Type
17.5.7.2.3. By Body Part
17.5.7.2.4. By Indication
17.5.7.2.5. By End User
17.6. Market Trends
17.7. Key Market Participants - Intensity Mapping
17.8. Drivers and Restraints - Impact Analysis
18. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2012 to 2022
18.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. India
18.3.1.2. Thailand
18.3.1.3. Indonesia
18.3.1.4. Malaysia
18.3.1.5. Rest of South Asia
18.3.2. By Product
18.3.3. By Test Type
18.3.4. By Body Part
18.3.5. By Indication
18.3.6. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Product
18.4.3. By Test Type
18.4.4. By Body Part
18.4.5. By Indication
18.4.6. By End User
18.5. Country Level Analysis & Forecast
18.5.1. India Market Analysis
18.5.1.1. .Introduction
18.5.1.2. Market Analysis and Forecast by Market Taxonomy
18.5.1.2.1. By Product
18.5.1.2.2. By Test Type
18.5.1.2.3. By Body Part
18.5.1.2.4. By Indication
18.5.1.2.5. By End User
18.5.2. Thailand Market Analysis
18.5.2.1. .Introduction
18.5.2.2. Market Analysis and Forecast by Market Taxonomy
18.5.2.2.1. By Product
18.5.2.2.2. By Test Type
18.5.2.2.3. By Body Part
18.5.2.2.4. By Indication
18.5.2.2.5. By End User
18.5.3. Indonesia Market Analysis
18.5.3.1. Introduction
18.5.3.2. Market Analysis and Forecast by Market Taxonomy
18.5.3.2.1. By Product
18.5.3.2.2. By Test Type
18.5.3.2.3. By Body Part
18.5.3.2.4. By Indication
18.5.3.2.5. By End User
18.5.4. Malaysia Market Analysis
18.5.4.1. Introduction
18.5.4.2. Market Analysis and Forecast by Market Taxonomy
18.5.4.2.1. By Product
18.5.4.2.2. By Test Type
18.5.4.2.3. By Body Part
18.5.4.2.4. By Indication
18.5.4.2.5. By End User
18.6. Market Trends
18.7. Key Market Participants - Intensity Mapping
18.8. Drivers and Restraints - Impact Analysis
19. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2012 to 2022
19.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. China
19.3.1.2. Japan
19.3.1.3. South Korea
19.3.2. By Product
19.3.3. By Test Type
19.3.4. By Body Part
19.3.5. By Indication
19.3.6. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Product
19.4.3. By Test Type
19.4.4. By Body Part
19.4.5. By Indication
19.4.6. By End User
19.5. Country Level Analysis & Forecast
19.5.1. China Market Analysis
19.5.1.1. .Introduction
19.5.1.2. Market Analysis and Forecast by Market Taxonomy
19.5.1.2.1. By Product
19.5.1.2.2. By Test Type
19.5.1.2.3. By Body Part
19.5.1.2.4. By Indication
19.5.1.2.5. By End User
19.5.2. Japan Market Analysis
19.5.2.1. Introduction
19.5.2.2. Market Analysis and Forecast by Market Taxonomy
19.5.2.2.1. By Product
19.5.2.2.2. By Test Type
19.5.2.2.3. By Body Part
19.5.2.2.4. By Indication
19.5.2.2.5. By End User
19.5.3. South Korea Market Analysis
19.5.3.1. Introduction
19.5.3.2. Market Analysis and Forecast by Market Taxonomy
19.5.3.2.1. By Product
19.5.3.2.2. By Test Type
19.5.3.2.3. By Body Part
19.5.3.2.4. By Indication
19.5.3.2.5. By End User
19.6. Market Trends
19.7. Key Market Participants - Intensity Mapping
19.8. Drivers and Restraints - Impact Analysis
20. Oceania Market Analysis 2012 to 2022 and Forecast 2023 to 2033
20.1. Introduction
20.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2012 to 2022
20.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
20.3.1. By Country
20.3.1.1. Australia
20.3.1.2. New Zealand
20.3.2. By Product
20.3.3. By Test Type
20.3.4. By Body Part
20.3.5. By Indication
20.3.6. By End User
20.4. Market Attractiveness Analysis
20.4.1. By Country
20.4.2. By Product
20.4.3. By Test Type
20.4.4. By Body Part
20.4.5. By Indication
20.4.6. By End User
20.5. Country Level Analysis & Forecast
20.5.1. Australia Market Analysis
20.5.1.1. .Introduction
20.5.1.2. Market Analysis and Forecast by Market Taxonomy
20.5.1.2.1. By Product
20.5.1.2.2. By Test Type
20.5.1.2.3. By Body Part
20.5.1.2.4. By Indication
20.5.1.2.5. By End User
20.5.2. New Zealand Market Analysis
20.5.2.1. Introduction
20.5.2.2. Market Analysis and Forecast by Market Taxonomy
20.5.2.2.1. By Product
20.5.2.2.2. By Test Type
20.5.2.2.3. By Body Part
20.5.2.2.4. By Indication
20.5.2.2.5. By End User
20.6. Market Trends
20.7. Key Market Participants - Intensity Mapping
20.8. Drivers and Restraints - Impact Analysis
21. Middle East and Africa Market Analysis 2012 to 2022 and Forecast 2023 to 2033
21.1. Introduction
21.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2012 to 2022
21.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
21.3.1. By Country
21.3.1.1. GCC Countries
21.3.1.2. Türkiye
21.3.1.3. Northern Africa
21.3.1.4. South Africa
21.3.1.5. Rest of Middle East and Africa
21.3.2. By Product
21.3.3. By Test Type
21.3.4. By Body Part
21.3.5. By Indication
21.3.6. By End User
21.4. Market Attractiveness Analysis
21.4.1. By Country
21.4.2. By Product
21.4.3. By Test Type
21.4.4. By Body Part
21.4.5. By Indication
21.4.6. By End User
21.5. Country Level Analysis & Forecast
21.5.1. GCC Countries Market Analysis
21.5.1.1. .Introduction
21.5.1.2. Market Analysis and Forecast by Market Taxonomy
21.5.1.2.1. By Product
21.5.1.2.2. By Test Type
21.5.1.2.3. By Body Part
21.5.1.2.4. By Indication
21.5.1.2.5. By End User
21.5.2. Türkiye Market Analysis
21.5.2.1. Introduction
21.5.2.2. Market Analysis and Forecast by Market Taxonomy
21.5.2.2.1. By Product
21.5.2.2.2. By Test Type
21.5.2.2.3. By Body Part
21.5.2.2.4. By Indication
21.5.2.2.5. By End User
21.5.3. Northern Africa Market Analysis
21.5.3.1. Introduction
21.5.3.2. Market Analysis and Forecast by Market Taxonomy
21.5.3.2.1. By Product
21.5.3.2.2. By Test Type
21.5.3.2.3. By Body Part
21.5.3.2.4. By Indication
21.5.3.2.5. By End User
21.5.4. South Africa Market Analysis
21.5.4.1. Introduction
21.5.4.2. Market Analysis and Forecast by Market Taxonomy
21.5.4.2.1. By Product
21.5.4.2.2. By Test Type
21.5.4.2.3. By Body Part
21.5.4.2.4. By Indication
21.5.4.2.5. By End User
21.6. Market Trends
21.7. Key Market Participants - Intensity Mapping
21.8. Drivers and Restraints - Impact Analysis
22. Market Structure Analysis
22.1. Market Analysis by Tier of Companies
22.2. Market Share Analysis of Top Players
22.3. Market Presence Analysis
23. Competition Analysis
23.1. Competition Dashboard
23.2. Competition Benchmarking
23.3. Competition Deep Dive
23.3.1. Hologic Inc.
23.3.1.1. Overview
23.3.1.2. Product Portfolio
23.3.1.3. Key Financials
23.3.1.4. Sales Footprint
23.3.1.5. SWOT Analysis
23.3.1.6. Strategy Overview
23.3.1.6.1. Marketing Strategy
23.3.1.6.2. Product Strategy
23.3.1.6.3. Channel Strategy
23.3.2. Becton, Dickinson and Company
23.3.2.1. Overview
23.3.2.2. Product Portfolio
23.3.2.3. Key Financials
23.3.2.4. Sales Footprint
23.3.2.5. SWOT Analysis
23.3.2.6. Strategy Overview
23.3.2.6.1. Marketing Strategy
23.3.2.6.2. Product Strategy
23.3.2.6.3. Channel Strategy
23.3.3. Natureland Health
23.3.3.1. Overview
23.3.3.2. Product Portfolio
23.3.3.3. Key Financials
23.3.3.4. Sales Footprint
23.3.3.5. SWOT Analysis
23.3.3.6. Strategy Overview
23.3.3.6.1. Marketing Strategy
23.3.3.6.2. Product Strategy
23.3.3.6.3. Channel Strategy
23.3.4. Stix's
23.3.4.1. Overview
23.3.4.2. Product Portfolio
23.3.4.3. Key Financials
23.3.4.4. Sales Footprint
23.3.4.5. SWOT Analysis
23.3.4.6. Strategy Overview
23.3.4.6.1. Marketing Strategy
23.3.4.6.2. Product Strategy
23.3.4.6.3. Channel Strategy
23.3.5. PGYARD
23.3.5.1. Overview
23.3.5.2. Product Portfolio
23.3.5.3. Key Financials
23.3.5.4. Sales Footprint
23.3.5.5. SWOT Analysis
23.3.5.6. Strategy Overview
23.3.5.6.1. Marketing Strategy
23.3.5.6.2. Product Strategy
23.3.5.6.3. Channel Strategy
23.3.6. myLAB Box
23.3.6.1. Overview
23.3.6.2. Product Portfolio
23.3.6.3. Key Financials
23.3.6.4. Sales Footprint
23.3.6.5. SWOT Analysis
23.3.6.6. Strategy Overview
23.3.6.6.1. Marketing Strategy
23.3.6.6.2. Product Strategy
23.3.6.6.3. Channel Strategy
23.3.7. Juno Bio
23.3.7.1. Overview
23.3.7.2. Product Portfolio
23.3.7.3. Key Financials
23.3.7.4. Sales Footprint
23.3.7.5. SWOT Analysis
23.3.7.6. Strategy Overview
23.3.7.6.1. Marketing Strategy
23.3.7.6.2. Product Strategy
23.3.7.6.3. Channel Strategy
23.3.8. Seroflora
23.3.8.1. Overview
23.3.8.2. Product Portfolio
23.3.8.3. Key Financials
23.3.8.4. Sales Footprint
23.3.8.5. SWOT Analysis
23.3.8.6. Strategy Overview
23.3.8.6.1. Marketing Strategy
23.3.8.6.2. Product Strategy
23.3.8.6.3. Channel Strategy
23.3.9. PrivaPath Diagnostics
23.3.9.1. Overview
23.3.9.2. Product Portfolio
23.3.9.3. Key Financials
23.3.9.4. Sales Footprint
23.3.9.5. SWOT Analysis
23.3.9.6. Strategy Overview
23.3.9.6.1. Marketing Strategy
23.3.9.6.2. Product Strategy
23.3.9.6.3. Channel Strategy
23.3.10. NutraBlast
23.3.10.1. Overview
23.3.10.2. Product Portfolio
23.3.10.3. Key Financials
23.3.10.4. Sales Footprint
23.3.10.5. SWOT Analysis
23.3.10.6. Strategy Overview
23.3.10.6.1. Marketing Strategy
23.3.10.6.2. Product Strategy
23.3.10.6.3. Channel Strategy
23.3.11. Rite Aid Corporation
23.3.11.1. Overview
23.3.11.2. Product Portfolio
23.3.11.3. Key Financials
23.3.11.4. Sales Footprint
23.3.11.5. SWOT Analysis
23.3.11.6. Strategy Overview
23.3.11.6.1. Marketing Strategy
23.3.11.6.2. Product Strategy
23.3.11.6.3. Channel Strategy
23.3.12. Home Health (UK) Ltd
23.3.12.1. Overview
23.3.12.2. Product Portfolio
23.3.12.3. Key Financials
23.3.12.4. Sales Footprint
23.3.12.5. SWOT Analysis
23.3.12.6. Strategy Overview
23.3.12.6.1. Marketing Strategy
23.3.12.6.2. Product Strategy
23.3.12.6.3. Channel Strategy
23.3.13. Loyalbody
23.3.13.1. Overview
23.3.13.2. Product Portfolio
23.3.13.3. Key Financials
23.3.13.4. Sales Footprint
23.3.13.5. SWOT Analysis
23.3.13.6. Strategy Overview
23.3.13.6.1. Marketing Strategy
23.3.13.6.2. Product Strategy
23.3.13.6.3. Channel Strategy
23.3.14. Savyon Diagnostics
23.3.14.1. Overview
23.3.14.2. Product Portfolio
23.3.14.3. Key Financials
23.3.14.4. Sales Footprint
23.3.14.5. SWOT Analysis
23.3.14.6. Strategy Overview
23.3.14.6.1. Marketing Strategy
23.3.14.6.2. Product Strategy
23.3.14.6.3. Channel Strategy
23.3.15. BIOSYNEX SA
23.3.15.1. Overview
23.3.15.2. Product Portfolio
23.3.15.3. Key Financials
23.3.15.4. Sales Footprint
23.3.15.5. SWOT Analysis
23.3.15.6. Strategy Overview
23.3.15.6.1. Marketing Strategy
23.3.15.6.2. Product Strategy
23.3.15.6.3. Channel Strategy
23.3.16. Quantbiome, Inc.
23.3.16.1. Overview
23.3.16.2. Product Portfolio
23.3.16.3. Key Financials
23.3.16.4. Sales Footprint
23.3.16.5. SWOT Analysis
23.3.16.6. Strategy Overview
23.3.16.6.1. Marketing Strategy
23.3.16.6.2. Product Strategy
23.3.16.6.3. Channel Strategy
24. Assumptions and Acronyms Used
25. Research Methodology
Explore Healthcare Insights
View Reports
Yeast Infection Diagnostics Market
